SYK Initiates Coverage On Stryker by Barclays -- Rating Set to O

Stryker (SYK) announced CEO Kevin Lobo will step down at year-end, with President Spencer Stiles taking over. Shares have fallen 9.15% over the past month and 15.81% over the last quarter, though they remain positive over 3 and 5 years. The company trades at a discount to intrinsic value and analyst targets, with revenue growth expectations of 9-11% annually.

Stryker (SYK) announced a leadership transition, with Kevin Lobo becoming Executive Chair and Spencer Stiles taking over as CEO in 2027. The stock has declined 8.2% over 30 days and 14.9% over 90 days, but remains up 13.6% over 5 years. The company reported $25.8B in annual revenue and $3.7B in net income. Analysts suggest the stock is undervalued at $278.20, with a fair value estimate of $311.21, citing long-term growth prospects and recurring revenue.

Stryker Corp (SYK) shares rose after Barclays initiated bullish coverage on the medical technology sector, citing attractive valuations. Barclays set a $375 price target, highlighting Stryker's undervaluation by 33.8% according to GF Value™. The company has a GF Score™ of 90/100, reflecting strong financial health and growth. Insider activity shows significant net selling, while 11 top gurus hold mixed positions.

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Barclays initiated coverage on 26 medical technology companies, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. The firm sees current valuations as attractive and expects revenue stabilization to boost sentiment. Price targets: SYK at $375, ABT at $120.

Baird reiterated an Outperform rating and $385 price target for Stryker (SYK) after its planned CEO transition. The stock is down 20% year-to-date. Analysts have mixed reactions, with some lowering estimates due to orthopedic and Inari issues, while others remain optimistic about the transition.